When a person experiences arrhythmia (ie,
Epinephrine generally has been the vasopressor of choice for the treatment of VF or pulseless VT. 2 Epinephrine stimulates alpha-adrenergic receptors on smooth muscle of peripheral vessels, resulting in arterial vasoconstriction. Epinephrine also stimulates beta 1 receptors on the heart. Beta stimulation causes an increase in myocardial contractility, heart rate, and cardiac output. The goal of therapy is to limit perfusion to nonvital organs, such as the kidneys and the gastrointestinal tract, and to promote perfusion to the heart and brain. However, excessive beta stimulation may cause myocardial dysfunction in the postresuscitation period, especially in patients with underlying coronary artery disease. 4 Vasopressin is a naturally occurring antidiuretic hormone. When used at high doses, it stimulates V1 receptors on smooth muscle and acts as a potent peripheral vasoconstrictor. Studies have shown that endogenous levels of vasopressin are higher in patients who survive cardiac arrest than in those who do not have return of spontaneous circulation. 5, 6 In addition, vasopressin does not stimulate beta receptors and may cause less myocardial dysfunction than epinephrine.
A randomized trial compared vasopressin and epinephrine in patients with out-of-hospital cardiac arrest. One arm of the study was given standard advanced cardiac life support treatment with epinephrine, and the other arm was given vasopressin. No difference was observed between the two arms in the primary end point: successful resuscitation. However, significantly more patients in the vasopressin group survived for at least 24 hours. 7 On the basis of the results from this trial, the advanced cardiac life support guidelines include epinephrine and vasopressin as appropriate treatment for shock refractory VF and pulseless VT.
The American Heart Association guidelines for advanced cardiac life support state that antiarrhythmic medications should be considered for the treatment of shock refractory ventricular arrhythmias.
1,2 However, there is limited evidence available to guide medication selection when VF or pulseless VT persists. Amiodarone is an antiarrhythmic agent that has sodium, potassium, and calcium, as well as alpha-and beta-adrenergicblocking properties. 8 The Amiodarone in Out-of-Hospital Resuscitation of Refractory Sustained Ventricular Tachyarrhythmias (ARREST) trial was a randomized, doubleblind controlled trial conducted to determine whether antiarrhythmic drugs improve the rate of successful resuscitation after cardiac arrest.
This study enrolled 504 patients with nontraumatic outof-hospital cardiac arrest in whom VF or pulseless VT was present after first responders gave 3 shocks with an automatic external defibrillation. Advanced cardiac life support was initiated when paramedics arrived. Patients were intubated and then received 1 mg of epinephrine intravenous push followed by either 300 mg of amiodarone intravenous push or a placebo. The primary end point was admission to the hospital with a spontaneously perfusing rhythm.
The baseline characteristics of the 2 groups were similar. At the time of drug administration, 88% of the patients had VF, 7% had pulseless VT, and 5% had a pulseless rhythm that was not documented. A higher percentage of the patients randomized to amiodarone (44%) survived to hospital admission than those who received a placebo (34%) (P = .03). 9 However, the patients who had received amiodarone were more likely to experience hypotension and bradycardia. The study was not powered to detect a difference in survival to discharge.
Lidocaine is a sodium-channel blocker that causes a decrease in depolarization and automaticity of the ventricles. 8 The Amiodarone Versus Lidocaine in Prehospital VF Evaluation (ALIVE) trial, a randomized, double-blind controlled trial, compared amiodarone with lidocaine in patients with nontraumatic out-of-hospital VF. This study enrolled 347 patients who had persistent VF despite 3 shocks from an external defibrillator, a dose of epinephrine, and a fourth shock for patients who had recurrent VF despite successful initial defibrillation. The patients were randomized to receive either a 5-mg/kg amiodarone intravenous push or a 1.5-mg/kg lidocaine intravenous push. A repeat dose of amiodarone 2.5 mg/kg or lidocaine 1.5 mg/kg was given if VF persisted after an additional shock. The primary end point was survival to hospital admission.
There were no significant differences between the baseline characteristics of the 2 groups. However, significantly more patients in the amiodarone group (22.8%) survived to hospital admission than in the lidocaine group (12%) (P = .009). 10 Evaluation of time to drug administration showed that the survival advantage was lost if treatment was initiated more than 24 minutes after the cardiac arrest. The study was not large enough to evaluate survival to hospital discharge.
Procainamide is a sodium-channel blocker. However, unlike lidocaine, it decreases depolarization and impulse conduction in the atria, atrioventricular node, Bundle of His, and ventricles. 8 There are limited data to support the use of procainamide in the treatment of VF or pulseless VT. The only data available for the use of procainamide during cardiac arrest are retrospective evaluations of 20 patients in VF. 11 Because of its complicated dosing regimen and lack of evidence, procainamide should be considered for the treatment of VF or pulseless VT only if amiodarone or lidocaine fails or is contraindicated (Table 1) .
Pulseless electrical activity (PEA) is the loss of mechanical cardiac contractility despite the presence of electrical activity in the myocardium. Basically, an organized rhythm is detected on electrocardiogram (ECG), but a pulse cannot be palpated. Successful treatment of PEA is dependent on identification and treatment of the underlying cause.
• PULSELESS ELECTRICAL ACTIVITY node automaticity and AV node conduction. The clinical effects of atropine are an increase in heart rate, blood pressure, and systemic vascular resistance. 4 Atropine should not be used in combination with epinephrine for the treatment of PEA if the ECG shows a tachyarrhythmia. [1] [2] [3] The prognosis for patients in asystole is poor. Only 1 to 2 of 100 patients survive.
2 Lack of electrical activity should be confirmed by checking for proper ECG lead placement and looking for asystole in at least 2 leads. Treatment of asystole is similar to that for PEA, with emphasis on identifying and treating the underlying cause. Pharmacologic management includes a 1-mg epinephrine intravenous push every 3 to 5 minutes alternated with a 1-mg atropine intravenous push every 3 to 5 minutes, up to a maximum dose of 0.04 mg/kg. [1] [2] [3] The duration of resuscitative efforts requires consideration of the wishes of the patient and family members, underlying comorbidities, and duration of cardiac arrest.
Bradycardia may be associated with symptoms such as chest pain, shortness of breath, and a decreased level of consciousness. The patient also may have signs of low Possible causes include the five H's: hypovolemia, hypoxia, hydrogen ion (ie, acidosis), hyper/hypokalemia, and hypothermia (Table 2 ). Other possible causes are the five T's: tablets (ie, overdose of tricyclic antidepressants, calcium-channel blockers, beta blockers, or digoxin), cardiac tamponade, tension pneumothorax, cardiac thrombosis, and pulmonary thrombosis. As the cause of PEA is being investigated, drug therapy should be initiated. Therapy includes a 1-mg epinephrine intravenous push every 3 to 5 minutes alternated with a 1-mg atropine intravenous push every 3 to 5 minutes. However, atropine should be used only if the underlying rhythm is slow, and the maximum dose that should be administered is 0.04 mg/kg. [1] [2] [3] Atropine is a parasympatholytic drug with vagolytic activity. It causes an increase in the rate of myocardial depolarization and in myocardial excitability, as well as a decrease in AV nodal delay. These actions increase sinus blood pressure, shock, pulmonary congestion, or heart failure. A 0.5-to 1-mg atropine intravenous push, up to a maximum dose of 0.04 mg/kg, should be administered immediately if first-degree heart block is detected. Atropine is not effective as treatment for bradycardia in patients with a heart transplant because it denervates the vagus nerve. If intravenous (IV) access is not available, transcutaneous pacing should be initiated without delay. Transcutaneous pacing is the treatment of choice for patients with advanced heart blocks, especially if the block is below the His-Purkinje level. A dopamine infusion at 5 to 20 mcg/kg per minute or an epinephrine infusion at 2 to 10 mcg per minute may be needed to help support blood pressure and heart rate. [1] [2] [3] If a patient already has central IV access, it should be used for drug administration. If IV access is not available, a peripheral catheter should be placed. A peripheral catheter can be placed more quickly than a central catheter when emergent medication administration is needed. After each medication is given, it should be followed immediately by a 20-mL bolus of normal saline. The extremity then should be elevated to facilitate circulation of the drug to the central circulation. Continued cardiopulmonary resuscitation also is imperative to help circulate the medication. 1 The endotracheal (ET) tube should be used for drug administration if IV access cannot be established. Epinephrine, vasopressin, lidocaine, and atropine can be given via the ET tube. In general, the ET dose is 2 to 2.5 times that of the normal recommended IV dose. 1 The only exception to this is vasopressin, for which the ET dose is the same as the IV dose. 3 The ET dose should be drawn up into a syringe, then diluted to a total volume of 10 mL with normal saline. The needle should be removed from the syringe to avoid administration of the drug via the wrong route. Before the medication is instilled into the ET tube, several brisk insufflations should be given using a bag valve mask. After administration of the medication in the ET tube, several quick insufflations should again be given to ensure that the medication is
• DRUG ADMINISTRATION FOR CARDIAC ARREST absorbed through the lung tissue and that it will reach the central circulation.
It is important to understand the role of medications in the treatment of potentially fatal arrhythmias. Healthcare providers should be familiar with the treatment algorithms for cardiac emergencies such as ventricular fibrillation, pulseless ventricular tachycardia, pulseless electrical activity, asystole, and severe bradycardia. A quick response with appropriate medical care will increase a patient's chance of survival.
